🚀 VC round data is live in beta, check it out!

Vicapsys Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vicapsys and similar public comparables like Labiana Health, Zhengye Biotechnology, Cynata Therapeutics, Annovis Bio and more.

Vicapsys Overview

About Vicapsys

Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.


Founded

1997

HQ

United States

Employees

2

Financials (FY)

Revenue:
EBITDA: ($1M)

EV

$48M

Valuation Multiples

Multiples.vc

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Vicapsys Financials

Vicapsys reported last fiscal year revenue of — and negative EBITDA of ($1M).

In the same fiscal year, Vicapsys generated ($1M) in EBITDA losses and had net loss of ($1M).


Vicapsys P&L

In the most recent fiscal year, Vicapsys reported revenue of and EBITDA of ($1M).

Vicapsys expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Vicapsys forward-looking valuation multiples
LTMNTMLast FYFY 2026FY 2027FY 2028
EBITDAXXX($1M)XXXXXXXXX
Net ProfitXXX($1M)XXXXXXXXX
Net Debt$344KXXXXXXXXX

Financial data powered by Morningstar, Inc.

Vicapsys Stock Performance

Vicapsys has current market cap of $47M, and enterprise value of $48M.

Market Cap Evolution


Vicapsys' stock price is $1.46.

See Vicapsys trading valuation data
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$48M$47M0.0%XXXXXXXXX$-0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Vicapsys Valuation Multiples

Vicapsys trades at (41.1x) EV/EBITDA.

See valuation multiples for Vicapsys and 15K+ public comps

Vicapsys Financial Valuation Multiples

As of April 11, 2026, Vicapsys has market cap of $47M and EV of $48M.

Equity research analysts estimate Vicapsys' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Vicapsys has a P/E ratio of (40.0x).

LTMNTMLast FYFY 2026FY 2027FY 2028
Market cap (current)$47MXXX$47MXXXXXXXXX
EV (current)$48MXXX$48MXXXXXXXXX
EV/EBITDAXXX(41.1x)XXXXXXXXX
EV/EBITXXX(45.6x)XXXXXXXXX
P/EXXX(40.0x)XXXXXXXXX
EV/FCFXXX(114.4x)XXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Vicapsys Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Vicapsys Margins & Growth Rates

Vicapsys' revenue in the last fiscal year grew by .

Vicapsys' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.

See operational valuation multiples for Vicapsys and other 15K+ public comps

Vicapsys Operational Valuation Multiples

LTMNTMLast FYFY 2026FY 2027FY 2028
Revenue per EmployeeXXX$0.0MXXXXXXXXX
Opex per EmployeeXXX$0.5MXXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Vicapsys Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

EV/RevenueEV/EBITDA
LTM2026E2027ELTM2026E2027E
Labiana HealthXXXXXXXXXXXXXXXXXX
Zhengye BiotechnologyXXXXXXXXXXXXXXXXXX
Cynata TherapeuticsXXXXXXXXXXXXXXXXXX
Annovis BioXXXXXXXXXXXXXXXXXX
Vivoryon TherapeuticsXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX

Valuation data powered by FactSet, Inc.

Vicapsys M&A Activity

Vicapsys acquired XXX companies to date.

Last acquisition by Vicapsys was on XXXXXXXX, XXXXX. Vicapsys acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See M&A valuation multiples

Latest Acquisitions by Vicapsys

Acquired CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.

Start Free Trial

Vicapsys Investment Activity

Vicapsys invested in XXX companies to date.

Vicapsys made its latest investment on XXXXXXXX, XXXXX. Vicapsys invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See VC round multiples

Latest Investments by Vicapsys

CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Vicapsys

When was Vicapsys founded?Vicapsys was founded in 1997.
Where is Vicapsys headquartered?Vicapsys is headquartered in United States.
How many employees does Vicapsys have?As of today, Vicapsys has over 2 employees.
Is Vicapsys publicly listed?Yes, Vicapsys is a public company listed on OTC Pink Sheets.
What is the stock symbol of Vicapsys?Vicapsys trades under VICP ticker.
Who are competitors of Vicapsys?Vicapsys main competitors are Labiana Health, Zhengye Biotechnology, Cynata Therapeutics, Annovis Bio.
What is the current market cap of Vicapsys?Vicapsys' current market cap is $47M.
Is Vicapsys profitable?No, Vicapsys is not profitable.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial